Other countries with prostate cancer screening activities have demonstrated similar prostate cancer detection rates, e.g., in Japan, municipality-based prostate screening detection rate was 0.5–1.1% [13], while the Finland section of ERSPC achieved a 2.5% detection rate with a PSA cut-off level of 4 ng/mL during first three years of the study, whereas the detection rate in the Dutch centre was 4.6%, and in the Italian centre 1.6% of men were screened [20,21]. The gene discussed is KLK3; the disease is prostate carcinoma.